GlassScriptPhysician profile
Alan Jeffrey Bloch
NPI 1477551893
$2,344.02
in general payments reported to CMS, 2019-2025
33 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Primary Podiatric Medicine provider received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $74.35 · 2021: $291 · 2022: $291 · 2023: $508 · 2024: $561 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $372.77 | 2019-2025 | Augment Injectable, Prophecy, Phalinx |
| Aroa Biosurgery Incorporated | $295.80 | 2022-2024 | |
| Paragon 28, INC. | $270.05 | 2019-2024 | Portfolio |
| Depuy Synthes Sales INC. | $126.79 | 2023-2025 | Motoband, Foot Osteotomy Wedge System |
| Fusion Orthopedics USA, LLC | $116.42 | 2025 | |
| Treace Medical Concepts, INC. | $101.76 | 2025 | |
| Kci USA, INC. | $91.57 | 2023 | Promogran Prisma, Activ.A.C., V.A.C.Instill |
| Pfizer INC. | $88.58 | 2019-2023 | |
| Solventum Corporation | $85.89 | 2024 | V.A.C.Instill, Activ.A.C. |
| Novo Nordisk INC | $75.34 | 2021-2024 | Wegovy |
| Zimmer Biomet Holdings, INC. | $70.54 | 2021-2022 | |
| Convatec INC. | $58.71 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $54.39 | 2024 | Nuzyra |
| Lilly USA, LLC | $51.60 | 2022-2024 | Mounjaro |
| Amgen INC. | $49.11 | 2021-2025 | Repatha, Otezla, Krystexxa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $46.88 | 2022-2024 | Proclaim, Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $37.86 | 2021-2023 | Eliquis |
| Acell, INC. | $36.00 | 2019-2020 | |
| Smith+Nephew, INC. | $31.02 | 2020-2024 | Collagenase Santyl |
| Bioventus LLC | $30.89 | 2021 | |
| Kerecis Limited | $28.25 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Anika Therapeutics, INC. | $28.20 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.47 | 2019 | |
| Integra Lifesciences Corporation | $21.79 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Tactile Systems Technology INC | $21.73 | 2025 | Nimbl, Flexitouch Plus |
| Organogenesis INC. | $21.19 | 2023 | Puraply |
| Merck Sharp & Dohme LLC | $17.06 | 2022 | |
| Glaxosmithkline, LLC. | $16.44 | 2021 | |
| Inari Medical, INC. | $15.72 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alfasigma USA, INC. | $15.22 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.64 | 2023 | Seglentis |
| Grt US Holding, INC. | $13.18 | 2021 | |
| Orthofix Medical, INC. | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.